{
  "abstract": "Hemophagocytic lymphohistiocytosis (HLH) complicating classic Hodgkin lymphoma (HL-HLH) is a rare but frequently life-threatening condition that is strongly associated with Epstein–Barr virus (EBV) infection, particularly in the mixed-cellularity and lymphocyte-depleted subtypes. No consensus has been reached regarding treatment for HL-HLH, and the myelotoxicity induced by etoposide-based HLH-directed therapy precludes its safe addition to intensive lymphoma-directed chemotherapy, particularly in older patients. We here report the case of a male in his early 70s with advanced EBV-positive mixed-cellularity classic Hodgkin lymphoma (CHL) who presented with cervical lymphadenopathy, fever, hepatosplenomegaly, and a markedly elevated soluble interleukin-2 receptor (sIL-2R) level, along with a high peripheral blood EBV DNA load. EBV-encoded small RNA in situ hybridization confirmed EBV positivity in lymphoma cells. His fever was steroid-refractory, and chemotherapy with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD) was initiated immediately following the diagnosis was confirmed. However, the persistent high fever did not resolve, and progressive cytopenia, marked hyperferritinemia, and further increase in sIL-2R levels were observed. Repeat bone marrow examinations revealed macrophage activation with hemophagocytosis, confirming HLH as a complication. Rituximab was promptly administered, and the fever resolved within 3 days. Furthermore, ferritin, sIL-2R, and lactate dehydrogenase levels substantially declined within 1 week, with peripheral blood EBV DNA becoming undetectable. BV-AVD was continued without major complications and led to a complete response after six cycles. Rituximab may represent a strategically timed and reasonable adjunctive intervention for EBV-driven HL-HLH that is refractory to, or develops following, chemotherapy for CHL.",
  "abstract_shown": true,
  "affiliations": [
    "Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Medical Student, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Division of Diagnostic Pathology, Tohoku Medical and Pharmaceutical University, Sendai, Japan"
  ],
  "article_type": "case report",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Satoshi Ichikawa"
    },
    {
      "affs": [
        0
      ],
      "name": "Yutaka Suzuki"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuya Tanaka"
    },
    {
      "affs": [
        0
      ],
      "name": "Keita Kanba"
    },
    {
      "affs": [
        0
      ],
      "name": "Kensuke Fujita"
    },
    {
      "affs": [
        0
      ],
      "name": "Yoko Okitsu"
    },
    {
      "affs": [
        0
      ],
      "name": "Masahiro Kobayashi"
    },
    {
      "affs": [
        0
      ],
      "name": "Fumiyoshi Fujishima"
    },
    {
      "affs": [
        0
      ],
      "name": "Junichi Kameoka"
    },
    {
      "affs": [
        0
      ],
      "name": "Tomonori Ishii"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/be2japr0h283g.bib",
  "cited_by": 0,
  "doi": "10.3960/jslrt.26032",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13759248/",
  "id": "be2japr0h283g",
  "issns": [
    "1346-4280",
    "1880-9952"
  ],
  "landing_url": "https://doi.org/10.3960/jslrt.26032",
  "language": "en",
  "licence": "CC-BY-NC-SA-4.0",
  "licence_label": "CC BY-NC-SA 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Case Report"
    ],
    [
      "openalex",
      "2720|Autoimmune and Inflammatory Disorders Research"
    ]
  ],
  "openalex": "W7204560072",
  "pdf_url": "https://www.jstage.jst.go.jp/article/jslrt/advpub/0/advpub_26032/_pdf",
  "pmcid": "PMC13759248",
  "pmid": "42669549",
  "published": "2026-08-29",
  "publisher": "Japanese Society for Lymphoreticular Tissue Research",
  "ris": "https://research.draconitic.com/paper/be2japr0h283g.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:23:55Z",
      "native_id": "PMC13759248",
      "source": "pmc",
      "url": "https://doi.org/10.3960/jslrt.26032"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2720|Autoimmune and Inflammatory Disorders Research",
      "subfield": "general"
    }
  ],
  "title": "Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein–Barr virus-positive classic Hodgkin lymphoma with rituximab",
  "title_text": "Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein–Barr virus-positive classic Hodgkin lymphoma with rituximab",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:23:55Z",
  "url": "https://research.draconitic.com/paper/be2japr0h283g",
  "venue": "Journal of Clinical and Experimental Hematopathology : JCEH",
  "versions": []
}